Results 41 to 50 of about 123,228 (148)

Spontaneous resolution of untreated diffuse large B‐cell lymphoma of maxillary bone after incisional biopsy

Clinical Case Reports, 2019
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous group of lymphomas which require multiagent therapy for remission induction and are associated with relapse in more than 40% of patients.
Lainey Flatow‐Trujillo, Khine Win, Amy Jencks, Leslie Andritsos, Cecilia Arana Yi   +4 more
doaj   +1 more source

Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

Haematologica, 2008
Background The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3+ regulatory T-cells (Treg) in lymphomas.Design and Methods The absolute number of intratumoral FOXP3+ cells ...
Alexandar Tzankov, Cecile Meier, Petra Hirschmann, Philip Went, Stefano A. Pileri, Stephan Dirnhofer   +5 more
doaj   +1 more source

Presentation_1_Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.pdf

, 2021
Jia Li (160557), Jianpeng Zhou (11780204), Wei Guo (86150), Xingtong Wang (663180), Yangzhi Zhao (6388370), Ou Bai (735631)   +5 more
openalex   +2 more sources

Sinonasal diffuse large B-cell lymphoma: own clinical observation and literature review

Онкогематология
Diffuse large B-cell lymphoma is the most common immunomorphological variant of lymphoma in adults. Extranodal lesions are observed in a third of patients at the disease onset.
M. A. Mingalimov, E. A. Baryakh, O. L. Kochneva, E. N. Misyurina, Yu. Yu. Polyakov, E. I. Zhelnova, K. V. Yatskov, A. B. Makeshova, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, D. V. Lebedev, E. N. Zotina, D. E. Gagloeva, M. M. Beregov, E. A. Mamatturdiev, I. V. Samsonova, M. A. Lysenko   +17 more
doaj   +1 more source

Supplementary Data 1 from Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

, 2023
Mark Roschewski, Manish R. Patel, Patrick M. Reagan, Nakhle S. Saba, Graham P. Collins, Hendrik‐Tobias Arkenau, Sven de Vos, Barrett Nuttall, Melih Acar, Kathleen A. Burke, Rafael D. White, Maria Udriste, Shringi Sharma, Brian Dougherty, Daniel Stetson, David F. Jenkins, Andrew Mortlock, Alessandra Forcina, Veerendra Munugalavadla, Ian W. Flinn   +19 more
openalex   +1 more source

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies

Journal of Hematology & Oncology
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable malignancy, that has had practice changing treatment approvals in both the frontline and relapsed setting in the last 5 years. Advent of novel therapeutic options in the recent years has
Allison M. Bock, Narendranath Epperla
doaj   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Refractory diffuse large B-cell Lymphoma

Journal of Taibah University Medical Sciences, 2023
Hajar Masrour, Latifa Lerhrib, Sanaa Bouchnafati, Widad Rhandour, Mounia Bouzayd, Laila Abarkan, Anas Oudrhiri, Nabil Al Saddiq, Rim Hanini, Yassine Chekkori, Falah Eddine Tohir, Ouazzani, Naoual Oubelkacem, Noufissa Alami Drideb, Zineb Khammar, Rhizlane Berrady   +15 more
doaj   +1 more source

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

Haematologica, 2010
Background BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome.
Jesse Shustik, Guangming Han, Pedro Farinha, Nathalie A. Johnson, Susana Ben Neriah, Joseph M. Connors, Laurie H. Sehn, Douglas E. Horsman, Randy D. Gascoyne, Christian Steidl   +9 more
doaj   +1 more source

Histone deacetylase inhibitors in adult patients with diffuse large b-cell lymphoma relapsed/refractory: a phase II study with Panobinostat [PDF]

, 2015
Cinzia Pellegrini
openalex   +1 more source